


CLAIMS:

1. A compound of formula I:



I

wherein n is 1 or 2;

R¹ represents CF₃ or C₁-₆alkyl, C₂-₆alkenyl, C₃-₉cycloalkyl or C₃-₆cycloalkylC₁-₆alkyl, any of which may bear up to 2 substituents selected from halogen, CN, CF₃, OR³, COR³, CO₂R³, OCOR⁴, SO₂R⁴, N(R⁵)₂, and CON(R⁵)₂,

or R¹ represents aryl, arylC₁-₆alkyl, C-heterocyclyl or C-heterocyclylC₁-₆alkyl;

R² represents H or C₁-₄alkyl;

R³ represents H, C₁-₄alkyl, phenyl or heteroaryl;

R⁴ represents C₁-₄alkyl, phenyl or heteroaryl;

R⁵ represents H or C₁-₄alkyl, or two R⁵ groups together with a nitrogen atom to which they are mutually attached complete an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or thiomorpholine-1,1-dioxide ring;


Ar¹ and Ar² independently represent phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, CHO, CH=NOH, C₁-₄alkoxy, C₁-₄alkoxycarbonyl, C₂-₆acyl, C₂-₆alkenyl and C₁-₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁-₄alkoxy;

aryl at every occurrence thereof refers to phenyl or heteroaryl which optionally bear up to 3 substituents selected from halogen, CN, NO₂, CF₃, OCF₃, OR³, COR³, CO₂R³, OCOR⁴, N(R⁵)₂, CON(R⁵)₂ and optionally-substituted C₁-₆alkyl, C₁-₆alkoxy, C₂-₆alkenyl or C₂-₆alkenyloxy wherein the substituent is selected from halogen, CN, CF₃, phenyl, OR³, CO₂R³, OCOR⁴, N(R⁵)₂ and CON(R⁵)₂; and

C-heterocyclyl and N-heterocyclyl at every occurrence thereof refer respectively to a heterocyclic ring system bonded through carbon or nitrogen, said ring system being non-aromatic and comprising up to 10 atoms, at least one of which is O, N or S, and optionally bearing up to 3 substituents selected from oxo, halogen, CN, NO₂, CF₃, OCF₃, OR³, COR³, CO₂R³, OCOR⁴, OSO₂R⁴, N(R⁵)₂, CON(R⁵)₂ and optionally-substituted phenyl, C₁₋₆alkyl, C₁₋₆alkoxy, C₂₋₆alkenyl or C₂₋₆alkenyloxy wherein the substituent is selected from halogen, CN, CF₃, OR³, CO₂R³, OCOR⁴, N(R⁵)₂ and CON(R⁵)₂;
or a pharmaceutically acceptable salt thereof.

2. A compound according to Claim 1 wherein Ar¹ is 6-trifluoromethyl-3-pyridyl, 4-chlorophenyl or 4-trifluoromethylphenyl and Ar² is 2,5-difluorophenyl.

3. A compound according to Claim 1 of formula II:



wherein X represents N or CH;

R⁶ represents H, F, Cl, Br, CN, CF₃, CH=CH₂ or CH₃;

R⁷ represents F, Cl, Br, CN, CH₃ or CH₂OH; and

R¹ is as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

4. A compound according to Claim 3 wherein R¹ is CF₃.


5. The compound according to Claim 4 which is trifluoromethanesulfonic acid, N-[4-(2,5-difluorophenyl)-4-(6-trifluoromethyl-pyridine-3-sulfonyl)-cyclohexyl]-amide or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound according to Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

7. A method of treatment of a subject suffering from or prone to a condition associated with the deposition of β -amyloid which comprises administering to the subject an effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

8. The method according to Claim 7 wherein the condition is Alzheimer's disease.

9. A process for preparing a compound according to Claim 1 in which R^2 is H comprising reacting a sulfinylchloride R^1SOCl or a sulfonyl chloride R^1SO_2Cl or a sulfonic anhydride $(R^1SO_2)_2O$ with an amine of formula III:



III

wherein R^1 , Ar^1 and Ar^2 are as defined in Claim 1.